⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked sharesUnlock shares

The morning catch up: ASX flat as investors await Melbourne Cup Day ‘safe bet’ rate rise

Published 07/11/2023, 09:43 am
Updated 07/11/2023, 10:00 am
© Reuters.  The morning catch up: ASX flat as investors await Melbourne Cup Day ‘safe bet’ rate rise
AXJO
-
GC
-
SI
-
CL
-
1YMH25
-

Australian shares are anticipated to start on a weaker note on this de facto public holiday for the nation, mirroring the subdued movements on Wall Street.

ASX futures pointed to a decline of 14 points, equivalent to 0.2%, settling at 6,990 early this morning.

Cash rate move a safe bet

All eyes are fixed not just on a horse race, but also on the outcome of today's Reserve Bank meeting, which is shaping up to be far more of a safe bet than the Melbourne Cup.

Expectations are leaning towards a quarter-point increment in the cash rate target, which would raise it to 4.35%.

Meanwhile, Wall Street displayed a mixed performance, with the Dow edging up by 0.1%, the S&P 500 showing a 0.2% increase and the Nasdaq gaining 0.3%.

In the wake of robust gains the previous week, US stocks saw incremental advances as investors meticulously analysed the latest earnings reports and economic indicators.

Last week, major indices surged on the optimistic belief that the Federal Reserve's rate hike cycle is approaching its conclusion.

During this trading session, the US dollar exhibited a modest strengthening alongside Treasury yields, while oil prices received a slight boost. This came as Saudi Arabia and Russia confirmed their intentions to extend production cuts until the year's end.

The information technology and healthcare sectors shone as top performers, demonstrating strength in this market session. Conversely, real estate and energy sectors experienced declines of more than 1%.

This is how IG senior market analyst Tony Sycamore sees things unfolding today in the aftermath of the RBA’s meeting:

“Ahead of this afternoon's RBA board meeting, the rates market is assigning a 53% probability of a 25bp rate hike from the RBA to 4.35%.

“Given the political debate around whether Q3 inflation data represented a “material” change, it will be a close call. For the record, we expect the RBA to raise rates today by 25bp to 4.35%.

“Last week's close above 6,950 negated the technical damage following October's sell-off. If the ASX200 can close above 7,000 after today's RBA board meeting, it will provide a platform for the ASX200 to test the 200-day moving average at 7,200, with scope to range highs at 7,400.”

Commodities

The price of WTI Crude Oil has shown an upward trajectory, currently standing at $80.92, representing a 0.51% increase.

This upward movement is attributed to the official confirmation of Saudi and Russian decisions to extend production cuts throughout the remainder of the year.

Gold's market performance has taken a downward turn, with the current price at $1,980, a decline of 0.61%, in response to the overnight surge in US yields.

Sycamore’s view is that as long as gold maintains its position above the 200-day moving average at $1,933 the recent drop from its recent peak of $2,009 should be interpreted as a correction rather than a definitive reversal towards a lower trajectory.

What’s happening in small caps?

The S&P/ASX Small Ordinaries closed at 2,668.64 yesterday, shedding 4.14% on the previous day.

Making news this morning, which you can read more about throughout the day with Proactive:

  • Race Oncology Ltd (ASX:RAC) has released interim clinical results from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory Acute Myeloid Leukaemia (R/R AML) patients.
  • AdAlta Ltd (ASX:1AD) has raised $1.65 million to fund completion of Phase 1 extension clinical study of AD-214 and to progress ongoing partnering discussions.
  • Aeris Resources Ltd (ASX:AIS, OTC:ARSRF) has delivered an update on exploration activities at the Constellation deposit, within the company’s 100% owned Tritton tenement package in New South Wales.
  • Island Pharmaceuticals Ltd (ASX:ILA) has garnered Human Research Ethics Committee (HREC) approval to commence its Single Ascending Dose study of ISLA-101 for the prevention and treatment of dengue and other mosquito (or vector) borne diseases.
  • OD6 Metals Ltd (ASX:OD6) has reported that metallurgical tests conducted by the Australian Nuclear Science Organisation (ANSTO) pave the way for attractive processing economics.
  • Read more on Proactive Investors AU

    Disclaimer

    Latest comments

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2025 - Fusion Media Limited. All Rights Reserved.